**Prostate cancer: (Salvage) surgery and outcome**

**Expert-Guided Poster Tour 4**

**Sunday 18 March**

**15:45 - 16:45**

**Location:** Green Area

**Chairs:**

P. Albers, Düsseldorf (DE)  
A. Villers, Lille (FR)

The Expert-Guided Poster Tour is a new innovative session type. The Tour aims to provide an interactive platform informing delegates on the real essentials and providing in-depth information on the different research projects. The Expert-Guided Poster Tour consists of two parts: The first part is reserved for poster viewing. The posters will be on display for 2 hrs before the start of the Guided Poster Tour. During the second part of the Tour, the two experts acting as moderators, will ask questions to poster presenters.

<table>
<thead>
<tr>
<th>PT074</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Burden of lymph node metastases in patients with prostate cancer treated with radical prostatectomy and lymph node dissection</strong></td>
</tr>
<tr>
<td><strong>By:</strong> Preisser F. 1, Marchioni M. 2, Bandini M. 3, Saad F. 4, Graefen M. 5, Tilki D. 5, Karakiewicz P.I. 4</td>
</tr>
<tr>
<td>1 University Hospital Hamburg-Eppendorf, Hamburg, Germany, Martini-Klinik Prostate Cancer Center, Hamburg, Germany, 2 SS Annunziata Hospital, Dept. of Urology, Chieti, Italy, 3 Urological Research Institute, IRCCS San Raffaele Scientific Institute, Dept. of Urology and Division of Experimental Oncology, Milan, Italy, 4 University of Montreal Health Center, Division of Urology, Cancer Prognostics and Health Outcomes Unit, Montreal, Canada, 5 University Hospital Hamburg-Eppendorf, Martini-Klinik Prostate Cancer Center, Hamburg, Germany</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>PT075</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Care pathways for the management of localised and locally advanced prostate cancer: Experience of the EAU guidelines office</strong></td>
</tr>
<tr>
<td><strong>By:</strong> Dimitropoulos K. 1, Cornford P. 2, De Santis M. 3, Mason M. 4, Rouviere O. 5, Bolla M. 6, Briganti A. 7, Fossati N. 7, Gandaglia G. 7, Maclennan S. 8, Maclennan S. 8, N'Dow J. 8, Omar I. 9, Plass K. 9, Royle J. 1, Van Den Bergh R. 10, Van Der Poel H. 10, Wiegel T. 11, Mottet N. 12</td>
</tr>
<tr>
<td>1 Aberdeen Royal Infirmary, Dept. of Urology, Aberdeen, United Kingdom, 2 Royal Liverpool and Broadgreen Hospitals NHS Trust, Dept. of Urology, Liverpool, United Kingdom, 3 University of Warwick, Cancer Research Centre, Coventry, United Kingdom, 4 Velindre Cancer Centre, Dept. of Clinical Oncology, Cardiff, United Kingdom, 5 Hospices Civils de Lyon, Edouard Herriot Hospital, Radiology Department, Lyon, France, 6 CHU Grenoble, Dept. of Radiation Therapy, Grenoble, France, 7 IRCCS Ospedale San Raffaele, Unit of Urology/Division of Oncology, UMI, Milan, Italy, 8 University of Aberdeen, Academic Urology Unit, Aberdeen, United Kingdom, 9 European Association of Urology, Guidelines Office, Arnhem, Netherlands, The, 10 Netherlands Cancer Institute, Dept. of Urology, Amsterdam, Netherlands, The, 11 University Hospital Ulm, Dept. of Radiation</td>
</tr>
</tbody>
</table>
PT076

Evaluating the psychometric properties of the EPIC-26

By: Crump T.¹, Peterson A.², Charbonneau C.³, Carlson K.¹, Sutherland J.², Baverstock R.¹

¹University of Calgary, Dept. of Surgery, Calgary, Canada, ²University of British Columbia, Centre for Health Services and Policy Research, Vancouver, Canada, ³Vesia, Alberta Bladder Centre, Calgary, Canada

PT077

Time to disease progression is a predictor of metastasis and mortality in patients with high-risk prostate cancer who achieved undetectable prostate-specific antigen following robot-assisted radical prostatectomy

To be confirmed

PT078

Causes of death in localised prostate cancer: Long term data from two phase III trials


¹Centre Hospitalier Universitaire De Sherbrooke, Dept. of Radio-Oncology, Sherbrooke, Canada, ²Centre Hospitalier Universitaire de Québec, Dept. of Radio-Oncology, Québec, Canada, ³Maisonneuve-Rosemont Hospital Montreal, Dept. of Radio-Oncology, Montreal, Canada, ⁴CSSS de Chicoutimi, Dept. of Radio-Oncology, Chicoutimi, Canada, ⁵Jewish General Hospital Montreal, Dept. of Radio-Oncology, Montreal, Canada, ⁶CSSS Gatineau, Dept. of Radio-Oncology, Gatineau, Canada, ⁷Centre Hospitalier Régional de Trois-Rivières, Dept. of Radio-Oncology, Trois-Rivières, Canada, ⁸CSSS Rimouski, Dept. of Radio-Oncology, Rimouski, Canada, ⁹Nova Scotia Cancer Centre, Dept. of Radio-Oncology, Halifax, Canada, ¹⁰Centre Hospitalier Universitaire De Montreal, Dept. of Radio-Oncology, Montreal, Canada, ¹¹Centre Hospitalier Universitaire De Québec, Dept. of Radio-Oncology, Québec, Canada, ¹²Université de Montreal, Dept. of Radio-Oncology, Montreal, Canada, ¹³McGill University Health Centre Montreal, Dept. of Radio-Oncology, Montreal, Canada

PT079

Which patients should be still considered for late salvage radiotherapy for rising or persistently elevated PSA after radical prostatectomy: Results from a large multi-institutional study

By: Noris Chiorda B.¹, Fossati N.¹, Karnes J.², Soligo M.², Boorjian S.², Bossi A.³, Coraggio G.³, Di Muzio N.⁴, Cozzarini C.⁴, Fiorino C.⁴, Gandaglia G.¹, Robesti D.¹, Bartkowiak D.⁵, Budach V.⁶, Shariat S.⁷, Goldner G.⁸, Battaglia A.⁹, Joniau S.⁹, Haustermans K.¹⁰, De Meerleer G.¹⁰, Fonteyne V.¹¹, Ost P.¹¹, Van Poppel H.⁹, Montorsi F.¹, Wiegel T.⁵, Briganti A.¹

¹Vita-Salute University San Raffaele, Dept. of Urology, Milan, Italy, ²Mayo Clinic, Dept. of Urology, Rochester, United States of America, ³Gustave Roussy Institute, Dept. of Radiation Oncology, Villejuif, France, ⁴San Raffaele Hospital, Dept. of Radiotherapy,
<table>
<thead>
<tr>
<th>Session ID</th>
<th>Title</th>
<th>Authors</th>
<th>Institutions</th>
</tr>
</thead>
<tbody>
<tr>
<td>PT080</td>
<td>Salvage radical prostatectomy (SRP) for radioresistant prostate cancer (PCA): Outcome analysis of 2 tertiary referral centres</td>
<td>By: Heidenreich A. 1, Alessandro M. 2, Soligo M. 2, Kohl T. 1, Grabbert M. 1, Pfister D. 1, Karnes J. 2</td>
<td>University of Cologne, Dept. of Urology, Cologne, Germany, Mayo Clinic, Dept. of Urology, Rochester, United States of America</td>
</tr>
<tr>
<td>PT081</td>
<td>Comparative effectiveness of salvage cryosurgery and high intensity focused ultrasound for radiorecurrent prostate cancer: A regression analysis</td>
<td>By: Peters M. 1, Dewar M. 2, Hetou K. 2, Noteboom J. 1, Tersteeg R. 1, Van Der Voort Van Zyp J. 1, Violette P. 3, Bauman G. 4, Chin J. 2</td>
<td>University Medical Centre Utrecht, Radiation Oncology, Utrecht, Netherlands, The, London Health Sciences Centre, Dept. of Urology, London, Canada, Woodstock Hospital, Dept. of Urology, Woodstock, Canada, London Health Sciences Centre, Radiation Oncology, London, Canada</td>
</tr>
<tr>
<td>PT082</td>
<td>Natural history of patients affected by nodal recurrence from prostate cancer treated with salvage lymph node dissection without additional treatments</td>
<td>By: Fossati N. 1, Suardi N. 1, Bravi C. 1, Soligo M. 2, Karnes J. 2, Schmautz M. 3, Heidenreich A. 3, Herlemann A. 4, Gratzke C. 4, Stief C. 4, Battaglia A. 5, Everaerts W. 5, Joniau S. 5, Van Poppel H. 5, Kalz A. 6, Osmonov D. 6, Juenemann K. 6, Rajarubendra N. 7, Gill L. 7, Mottrie A. 8, Briganti A. 1, Montorsi F. 1</td>
<td>Vita-Salute University San Raffaele, Dept. of Urology, Milan, Italy, Mayo Clinic, Dept. of Urology, Rochester, United States of America, University of Cologne, Dept. of Urology, Cologne, Germany, Ludwig-Maximilians-University, Dept. of Urology, Munich, Germany, University Hospital Leuven, Dept. of Urology, Leuven, Belgium, University Hospital Schleswig Holstein, Urology and Pediatric Urology, Campus Kiel, Germany, University of Southern California, USC Institute of Urology, Los Angeles, United States of America, OLV Ziekenhuis Aalst, Dept. of Urology, Melle, Belgium</td>
</tr>
<tr>
<td>PT083</td>
<td>Salvage lymphadenectomy in prostate cancer</td>
<td>By: Morozov A. , Bezrukov E. , Sukhanov R. , Sirota E. , Sliusarenco R. , Martirosyan G. Sechenov First Moscow State Medical University, Dept. of Urology, Moscow, Russia</td>
<td></td>
</tr>
<tr>
<td>PT084</td>
<td>Negative histology after salvage lymph node dissection for patients with PET/CT documented lymph node recurrence from prostate cancer: False positive findings or missed disease</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>
PT085

**Pathological landscape following salvage robot-assisted radical prostatectomy after focal high intensity focused ultrasound**


University College London Hospital, Dept. of Uro-oncology, London, United Kingdom

PT086

**The prognostic role of early PSA response after salvage radiation therapy: Long-term results from a multi-institutional study**


1Vita-Salute San Raffaele University, Dept. of Urology, Milan, Italy, 2Mayo Clinic, Dept. of Urology, Rochester, United States of America, 3University of Cologne, Dept. of Urology, Cologne, Germany, 4Ludwig Maximilians University, Dept. of Urology, Munich, Germany, 5University Hospital Leuven, Dept. of Urology, Leuven, Belgium, 6University Hospital Schleswig Holstein, Dept. of Urology, Campus Kiel, Germany, 7University of Southern California, Dept. of Urology, California, United States of America, 8OLV Ziekenhuis Aalst, Dept. of Urology, Melle, Belgium, 9Vita Salute University San Raffaele, Dept. of Urology, Milan, Italy

PT087

**Survival benefit of local vs. no local treatment for metastatic prostate cancer - impact of baseline PSA and metastatic substages**


1University Hospital Hamburg-Eppendorf, Martini-Klinik Prostate Cancer Center, Hamburg, Germany, 2University Hospital Hamburg-Eppendorf, Dept. of Urology, Hamburg, Germany, 3IRCCS San Raffaele Scientific Institute, Dept. of Urology and
### PT088

**The risk of cardiovascular disease following GnRH agonists versus antagonists: Real-world evidence from four European countries**

By: George G.¹, Scailteux L-M.², Garmo H.¹, Balussi F.³, De Coster G.⁴, De Schutter H.⁴, Kuiper J.⁵, Oger E.³, Verbeeck J.⁴, Van Hemelrijck M.¹

¹King’s College London, Dept. of Translational Oncology and Urology Research, London, United Kingdom, ²Rennes Hospital University, Pharmacovigilance Pharmacoepidemiology and Drug Information Center, Rennes, France, ³Rennes University, UPRES EA 7449 REPERES Pharmacoepidemiology and Health Services Research, Rennes, France, ⁴Belgian Cancer Registry, Brussels, Belgium, ⁵PHARMO Institute for Drug Outcomes Research, Utrecht, Netherlands, The

### PT089

**A meta-analysis of adverse events of degarelix versus luteinizing hormone agonists**

By: Jin C.¹, Cui C.², Zhang X.¹, Xu T.¹

¹Peking University People’s Hospital, Dept. of Urology, Beijing, China, ²Yale University School of Medicine, Dept. of Immunobiology, New Haven, United States of America

### PT090

**Quantitative assessment of bone scan to evaluate response in treatment with RA-223 in metastatic castration resistant prostate cancer (mCRPC)**

By: Anand A.¹, Lofgren A.¹, Tragardh E.², Edenbrandt L.³, Sandsén J.⁴, Beckman L.⁵, Svensson J.⁶, Karlsson C.⁷, Widmark A.⁷, Kindblom J.⁸, Ullen A.⁹, Bjartell A.¹⁰

¹Skane Hospital, Translational Medicine, Division of Urological Cancers, Malmo, Sweden, ²Skane University Hospital, Clinical Physiology and Nuclear Medicine, Malmo, Sweden, ³Gothenburg University, Dept. of Nuclear Medicine, Gothenburg, Sweden, ⁴Central Hospital Karlstad, Dept. of Oncology, Karlstad, Sweden, ⁵Sundsvall-Härnösand County Hospital, Dept. of Oncology, Sundsvall, Sweden, ⁶Skovde Hospital, Dept. of Urology, Skövde, Sweden, ⁷Umea University, Dept. of Radiation Sciences, Umea, Sweden, ⁸Gothenburg University, Dept. of Oncology, Gothenburg, Sweden, ⁹Karolinska University Hospital, Dept. of Oncology, Stockholm, Sweden, ¹⁰Skane Hospital, Dept. of Translational Medicine, Division of Urological Cancers, Malmo, Sweden

### PT091

**First interim results of PARABO: A non-interventional study evaluating patients with mCRPC with bone metastases treated with Radium-223 (Xofigo®) in a real life German practice setting**

By: Palmedo H.¹, Eschmann S.², Werner A.³, Selinski I.⁴, Möllers M.⁵, Pinkert J.⁶, Van Crüchten I.⁶, Neusser T.⁷, Pöppel T.⁶

¹Office based nuclear medicine center for Radiology, Nuclear Medicine, Bonn, Germany, ²Marienhospital, Nuclear Medicine, Stuttgart, Germany, ³Radiology Schwetzingen, Nuclear Medicine, Schwetzingen, Germany, ⁴Office based center for Radiology, Nuclear Medicine, Wiesbaden, Germany, ⁵Office based center for Radiology, Nuclear Medicine,
REASSURE observational study of radium-223 (Ra-223): First interim results by prior/concomitant treatment (Tx) in patients (Pts) with metastatic castration-resistant prostate cancer (mCRPC) enrolled in Europe

1 The Christie NHS Foundation Trust, Dept. of Oncology, Manchester, United Kingdom, 2 Universitätssklinikum Magdeburg, Dept. of Urology and Children Urology, Magdeburg, Germany, 3 University of Messina, Dept. of Nuclear Medicine, Messina, Italy, 4 ZNA Middelheim, Dept. of Oncology, Antwerp, Belgium, 5 Centralsjukhuset i Karlstad, Dept. of Oncology, Karlstad, Sweden, 6 Rigshospitalet, Dept. of Oncology, Copenhagen, Denmark, 7 Fondazione IRCCS Istituto Nazionale dei Tumori, Dept. of Radiotherapy and Oncology, Milan, Italy, 8 University of Göttingen, Dept. of Urology, Göttingen, Germany, 9 H. San Pedro de Alcántara, Dept. of Medical Oncology, Caceres, Spain, 10 Diakonissenkrankenhaus Dessau, Dept. of Urology, Dessau, Germany, 11 Benjamin Franklin Medical Center, Dept. of Oncology, Berlin, Germany, 12 Bayer, Dept. of Oncology, Basel, Switzerland, 13 Bayer, Dept. of Oncology, Whippany, United States of America, 14 San Camillo Forlanini Hospital, Dept. of Oncology, Rome, Italy, 15 UCL Saint Luc, Dept. of Urology, Sint-Lambrechts-Woluwe, Belgium
Baydon A.R. ²
¹Lister Hospital, Dept. of Urology, Stevenage, United Kingdom, ²University of Hertfordshire, Dept. of Pharmacology, Hatfield, United Kingdom, ³Lister Hospital, Dept. of Anaesthetics, Stevenage, United Kingdom

PT096

Using video analysis to understand the technical variation of robot-assisted radical prostatectomy (RARP) in a statewide surgical collaborative

By: Ghani K. ¹, Patel P. ², Kim T. ¹, Prebay Z. ³, Telang J. ¹, Linsell S. ¹, Kleer E. ³, Miller D. ¹, Peabody J. ⁴, Johnston W. ⁵
¹University of Michigan, Dept. of Urology, Ann Arbor, United States of America, ²Detroit Medical Center, Dept. of Urology, Detroit, United States of America, ³IHA Urology, Dept. of Urology, Ann Arbor, United States of America, ⁴Henry Ford Hospital, Dept. of Urology, Detroit, United States of America, ⁵Michigan Institute of Urology, Dept. of Urology, Novi, United States of America

PT097

Evaluating the predictive accuracy and the clinical benefit of a nomogram aimed to predict survival in node positive prostate cancer patients: External validation on a multi-institutional database

By: Schiavina R. ¹, Bianchi L. ¹, Marco B. ¹, Mineo Bianchi F. ¹, Briganti A. ², Carini M. ³, Terrone C. ⁴, Mottrie A. ⁵, Gacci M. ³, Gontero P. ⁶, Imbimbo C. ⁷, Marchioro G. ⁸, Milanese G. ⁹, Mirone V. ⁷, Montorsi F. ², Morgia G. ¹⁰, Novara G. ¹¹, Porreca A. ¹², Volpe A. ⁸, Brunocilla E. ¹
¹University of Bologna, Dept. of Urology, Bologna, Italy, ²URI, IRCCS Ospedale San Raffaele, Unit of Urology/Division of Oncology, Milan, Italy, ³University of Florence, Dept. of Urology, Florence, Italy, ⁴University of Genoa, Dept. of Urology, Genoa, Italy, ⁵OLV Hospital, Dept. of Urology, Aalst, Belgium, ⁶University of Turin, Dept. of Urology, Turin, Italy, ⁷University of Naples, Dept. of Urology, Naples, Italy, ⁸University of Eastern Piedmont, Dept. of Urology, Novara, Italy, ⁹University of Ancona, Dept. of Urology, Ancona, Italy, ¹⁰University of Catania, Dept. of Urology, Catania, Italy, ¹¹University of Padua, Dept. of Urology, Padua, Italy, ¹²Abano Hospital, Dept. of Urology, Abano Terme, Italy

PT098

What factors influence urinary continence after robot-assisted radical prostatectomy?

By: Zraik I.M. ¹, Musch M. ¹, Roggenbuck U. ², Loewen H. ¹, Krege S. ³, Kröpf D. ¹
¹Kliniken Essen-Mitte, Dept. of Urology, Essen, Germany, ²University Duisburg-Essen, Institute for Medical Informatics, Dept. of Biostatistics and Epidemiology, Essen, Germany, ³Kliniken Essen-Mitte, Dept. of Urology, Essen, Germany

PT099

Withdrawn
To be confirmed

PT100

Laparoscopic 3D-vision radical prostatectomy: A case series study on perioperative outcomes
### PT101

**Interrupted versus continuous suturing for the vesicourethral anastomosis during radical prostatectomy: A systematic review and meta-analysis**

By: Kowalewski K-F.¹, Tapking C.¹, Hetjens S.², Nickel F.¹, Mandel P.³, Ritter R.⁴, Kriegmair M.C.⁴

¹University of Heidelberg, Dept. of General, Visceral and Transplantation Surgery, Heidelberg, Germany, ²University Medical Center Mannheim, Dept. of Medical Statistics, Mannheim, Germany, ³University Medical Center Hamburg-Eppendorf, Dept. of Urology, Hamburg, Germany, ⁴University Medical Center Mannheim, Dept. of Urology, Mannheim, Germany

### PT102

**Withdrawn**

To be confirmed

### PT103

**Complications of robotic assisted laparoscopic prostatectomy - the first 1000 cases from a single surgeon series**

By: Nic An Riogh A.¹, O’ Meara S¹, Lundon D.¹, O’ Malley K.²

¹Mater Misericordiae University Hospital, Dept. of Urology, Dublin, Ireland, ²Mater Private Hospital, Dept. of Urology, Dublin, Ireland